MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 8, 2015, Pages 1017-1026

  Mussnich, Paula ^a,b   Rosa, Roberta ^a   Bianco, Roberto ^a   Fusco, Alfredo ^a,b,c   D'Angelo, Daniela ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b MINISTRY OF EDUCATION OF BRAZIL   (Brazil)

^c INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Colon cancer; drug resistance; miR 199a 5p; miR 375

Indexed keywords

CETUXIMAB; MICRORNA; MICRORNA 199A 5P; MICRORNA 375; PH DOMAIN AND LEUCINE RICH REPEAT PROTEIN PHOSPHATASE 1; PROTEIN KINASE B; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GENETIC MARKER; MIRN199 MICRORNA, HUMAN; MIRN375 MICRORNA, HUMAN; NUCLEAR PROTEIN; PHLPP1 PROTEIN, HUMAN; PHOSPHOPROTEIN PHOSPHATASE;

ARTICLE; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; DRUG TARGETING; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; UPREGULATION; COLONIC NEOPLASMS; DNA MICROARRAY; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETICS; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CETUXIMAB; COLONIC NEOPLASMS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENETIC MARKERS; HUMANS; MICRORNAS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHOPROTEIN PHOSPHATASES; UP-REGULATION;

EID: 84937151437     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2015.1057569     Document Type: Article

References (33)

1. Cunningham D, Atkin W, Lenz H-J, et al. Colorectal cancer. Lancet 2010;375(9719):1030-47
2. Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, et al. Acquired resistance to EGFR-targeted therapies in colorectal cancer. Mol Oncol 2014;8(6):1084-94
3. Camp ER, Summy J, Bauer TW, et al. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 2005;11(1):397-405
4. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136(2):215-33
5. Bandr-es E, Cubedo E, Agirre X, et al. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and nontumoral tissues. Mol Cancer 2006;5:29
6. Faltejskova P, Svoboda M, Srutova K, et al. Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med 2012;16(11):2655-66
7. Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol 2014;9287-314
8. Orang AV, Barzegari A. MicroRNAs in colorectal cancer: from diagnosis to targeted therapy. Asian Pac J Cancer Prev 2014;15(17):6989-99
9. Li T, Leong MH, Harms B, et al. MicroRNA-21 as a potential colon and rectal cancer biomarker. World J Gastroenterol 2013;19(34):5615-21
10. Xiao ZG, Deng ZS, Zhang YD, et al. Clinical significance of microRNA-93 downregulation in human colon cancer. Eur J Gastroenterol Hepatol 2013;25(3):296-301
11. Omrane I, Kourda N, Stambouli N, et al. MicroRNAs 146a and 147b biomarkers for colorectal tumor's localization. Biomed Res Int 2014;2014:584-852
12. Fang L, Li H, Wang L, et al. MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression. Oncotarget 2014;5(10):2974-87
13. Lee CG, McCarthy S, Gruidl M, et al. MicroRNA-147 induces a mesenchymal-to-epithelial transition (MET) and reverses EGFR inhibitor resistance. PLoS ONE 2014;9:e84597
14. Xu K, Liang X, Cui D, et al. MiR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drugsensitivity in human colorectal carcinoma cells. Mol Carcinog 2013;52(1):70-8
15. Ciardiello F, Bianco R, Caputo R, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004;10(2):784-93
16. Liu J, Weiss HL, Rychahou P, et al. Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis. Oncogene 2009;28(7):994-1004
17. D'Angelo D, Mussnich P, Rosa R, et al. High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs. BMC Cancer 2014;2:1-9
18. Bianco R, Rosa R, Damiano V, et al. Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. Clin Cancer Res 2008;14(16):5069-80
19. Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 2005;18(1):13-24
20. Wang S, Wang H, Davis BC, et al. PARP1 inhibitors attenuate AKT phosphorylation via the upregulation of PHLPP1. Biochem Biophys Res Commun 2011;412:379-84
21. Wu Q, Yang Z, Nie Y, et al. Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches. Cancer Lett 2014;347(2):159-66
22. Sui H, Cai G-X, Pan S-F, et al. MiR200c Attenuates P-gp-Mediated MDR and Metastasis by Targeting JNK2/c-Jun Signaling Pathway in Colorectal Cancer. Mol Cancer Ther 2014;13:3137-51
23. Bottai G, Pasculli B, Calin GA, Santarpia L. Targeting the microRNAregulating DNA damage/repair pathways in cancer. Expert Opin Biol Ther 2014;14:1667-83
24. Chen Y, Fu LL, Wen X, et al. Oncogenic and tumor suppressive roles of microRNAs in apoptosis and autophagy. Apoptosis 2014;19:1177-89
25. Vecchione A, Croce CM. Apoptomirs: Small molecules have gained the license to kill. Endocr Relat Cancer 2010;17(1):F37-50
26. Li X, Stevens PD, Liu J, et al. PHLPP is a negative regulator of RAF1, which reduces colorectal cancer cell motility and prevents tumor progression in mice. Gastroenterology 2014;146(5):1301-12
27. Liao WT, Li TT, Wang Z-G, et al. MicroRNA-224 promotes cell proliferation and tumor growth in human colorectal cancer by repressing PHLPP1 and PHLPP2. Clin Cancer Res 2013;19:4662-72
28. Shen Y, Wang P, Li Y, et al. MiR-375 is upregulated in acquired paclitaxel resistance in cervical cancer. Br J Cancer 2013;109(1):92-9
29. Streppel MM, Pai S, Campbell NR, et al. MicroRNA 223 is upregulated in the multistep progression of barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1. Clin Cancer Res 2013;19:4067-78
30. Cheng W, Liu T, Wan X, et al. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancerinitiating cells. FEBS J 2012;279:2047-59
31. Liu MX, Siu MKY, Liu SS, et al. Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer. Oncotarget 2013;5(4):944-58
32. Nagpal N, Ahmad HM, Molparia B, Kulshreshtha R. MicroRNA-191, an estrogen-responsive microRNA, functions as an oncogenic regulator in human breast cancer. Carcinogenesis 2013;34:1889-99
33. Di Leva G, Piovan C, Gasparini P, et al. Estrogen Mediated-Activation of miR-191/425 Cluster Modulates Tumorigenicity of Breast Cancer Cells Depending on Estrogen Receptor Status. PLoS Genet 2013;9(3):e1003311